Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Non-Hodgkin lymphoma, adult
Stage/Subtype:  indolent, stage I adult non-Hodgkin lymphoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 50 for your search:
Start Over
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR100955, NCI-2013-02262, 2012-004225-24, PCI-32765CAN3001, NCT01804686
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CC-5013-NHL-008, NCI-2015-00708, NCT01996865
Rituximab with or without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients with Untreated Follicular Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LS138D, NCI-2014-02476, NCT02320292
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: 95-024, NCI-2017-00824, MSKCC-95024, NCI-V95-0685, P30CA008748, NCT00002663
Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients with Epstein-Barr Virus-Positive Hematologic Malignancy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Any age
Trial IDs: ALCI, NCI-2012-00653, 9936-ALCI, H-9936, NCT00070226, NCT00671164, NCT00062868
Radiation Therapy and Rituximab in Treating Patients with Stage I-II Grade 1 or Grade 2 Follicular Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0283, NCI-2012-00734, NCT01473628
Dasatinib in Treating Patients with Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated with Autologous Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA-180-381, NCI-2012-00767, 1203010693, 2011-203, NCT01609816
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Brentuximab Vedotin and Rituximab in Treating Patients with Lymphomas Associated with Immunosuppression
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 12H09, NCI-2012-03090, STU00072695, NCT01805037
Recombinant Flt3 Ligand, Poly-ICLC, and Radiation Therapy in Treating Patients with Untreated, Relapsed, or Refractory Low Grade B-Cell or Cutaneous T Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-1347, NCI-2017-00655, NCT01976585
CD34+ Stem Cell Selection in Preventing Graft-Versus-Host Disease in Younger Patients with Malignant Disease Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Under 22
Trial IDs: AAAK8060, NCI-2014-00137, NCT02061800
Lenalidomide and Combination Chemotherapy in Treating Patients with MYC-Associated B-Cell Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-1406, NCI-2014-01581, IRB13-1406, NCT02213913
ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-LY-001, NCI-2015-00533, NCT02328014
Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IMDZ-G142, NCI-2015-01368, NCT02501473
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients with Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14H09, NCI-2015-00400, STU00200596, X16042, NCT02481310
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: eFT508-0002, NCI-2017-00209, NCT02937675
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Status: Enrolling by invitation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1103-CA, NCI-2011-00986, PCI-32765, NCT01109069
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Two Step Donor Stem Cell Transplant in Treating Patients with High-Risk Hematological Malignancies
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 08D.85, NCI-2012-00407, 2007-61, NCT01315132
Immune Therapy in Treating Patients with Epstein-Barr Virus Lymphoproliferative Disorders or Epstein-Barr Virus-Associated Malignancies
Status: Active
Phase: Phase II
Type: Diagnostic, Treatment
Age: any age
Trial IDs: 11-130, NCI-2012-00594, NCT01498484
Genetically Engineered Autologous T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 03712, NCI-2012-03024, NCT01747486
Bendamustine Hydrochloride and Rituximab Followed by Rituximab and Lenalidomide in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HO11414, NCI-2013-00485, 2012-0638, ML28201, RV-CLL/ -PI-0689, NCT01754857
Treatment for Advanced B-Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 3 to 31
Trial IDs: NYMC-157, NCI-2015-01702, L 10,753, NCT01859819
Safety Study of Cord Blood Units for Stem Cell Transplants
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Start Over